AGBL3 and B-cell chronic lymphocytic leukemia: When the analysis was restricted to cases diagnosed > 10 years after blood draw, anti-CCP3 appeared to remain protective for CLL but was not statistically significant (ORcontinuous = 0.73, 95% CI: 0.46–1.16, P = 0.18).